In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena [1] (multiple letters)

Annals of Neurology

Volumn 47, Issue 5, 2000, Pages 680-681

  Dufour, Anna ^a   Corsini, Elena ^a   Gelati, Maurizio ^a   Massa, Giorgio ^a   Tarcic, Nora ^a   Salmaggi, Andrea ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

BLOOD BRAIN BARRIER; BRAIN CELL; CELL ADHESION; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LETTER; LYMPHOCYTE MIGRATION; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0034098134     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200005)47:5<680::AID-ANA21>3.0.CO;2-9     Document Type: Letter

References (11)

1. Johnson KP, Brooks BR, Cohen JA, et al, and the Copolymer-1 Multiple Sclerosis Study Group. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
2. Johnson KP, Brooks BR, Cohen JA, et al, and the Copolymer-1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708
3. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer-1 induces suppressor T-cells of the TH2 type. Eur J Neurol 1996; 3(Suppl 4):029 (Abstract)
4. Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998;92:113-121
5. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer-1 to class II major histocompatibility complex molecules on living antigen presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 1994;91:4872-4876
6. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. Neurology 1998;50:1127-1133
7. Comi G, Filippi M. The effect of glatiramer acetate (Copaxone) on MRI-detected disease activity in patients with RRMS: a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. Multiple Sclerosis (In press)
8. Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
9. Prat A, Al-Asmi A, Duquette P, Antel JP. Lymphocyte migration and multiple sclerosis: relation with disease and therapy. Ann Neurol 1999;46:253-256
10. Benschop RJ, De Smet MBM, Bloem AC, Ballieux RE. Adhesion of subsets of human blood mononuclear cells to endothelial cells in vitro, as quantified by flow cytometry. Scand J Immunol 1992;36:793-800
11. Corsini E, Gelati M, Dufour A, et al. Reduction of transendothelial migration of mononuclear cells in IFN-β1b treated multiple sclerosis patients. Ann Neurol 1999;46:435 (Letter)